TargetBeta
ANGPTL3
angiopoietin like 3 · also ANGPT5 · Receptor ligands
3 programs in company-led studies act on ANGPTL3, from 3 companies: 2 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| SHR-1918 | Jiangsu HengRui Medicine | phase 3 | 85 running | – | the company's pipeline |
| VSA003rule | Visirna Therapeutics HK | phase 3 | 21 running | – | the studies' text |
| EDP167rule | Eddingpharm (Zhuhai) | phase 2 | 32 running | – | the studies' text |
Conditions their studies are in
- Homozygous Familial Hypercholesterolemia, 3 programs
- Dyslipidemias, 2 programs
- Hypercholesterolemia, 1 program
- Hyperlipidemias, 1 program
- Hypertriglyceridemia, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jun 2027SHR-1918 · Jiangsu HengRui Medicine · phase 3 · NCT07308392
- Nov 2027EDP167 · Eddingpharm (Zhuhai) · phase 2 · NCT07799129
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.